Bai Aotai: Signed authorization, production, supply, and commercialization protocol for BAT2306 (sukunumab) injection with Stein.

On December 16th, Jinshi Data News, the company signed an authorization license with SteinCares for the production, supply, and commercialization of the protocol, granting Stein the exclusive commercialization rights for the company's BAT2306 (Sikuchenyou monoclonal antibody) injection solution in the Brazilian and other Latin American markets. The transaction amount is up to a maximum of $8 million, including a $1.2 million down payment, a cumulative milestone payment of no more than $6.8 million, and a double-digit percentage of net sales as revenue sharing.

View Original
The content is for reference only, not a solicitation or offer. No investment, tax, or legal advice provided. See Disclaimer for more risks disclosure.
  • Reward
  • Comment
  • Share
Comment
0/400
No comments